Simultaneous determination of amlodipine besylate and atorvastatin calcium in binary mixture by spectrofluorimetry and HPLC coupled with fluorescence detection

Fine-tuning Fluorescence of Amlodipine Adopting on Blocking of Photoinduced Electron Transfer (PET): Application in Human Plasma

Assessing medication adherence through the determination of antihypertensive drugs in biological matrices holds significant importance. Amlodipine (AP), a potent antihypertensive medication extensively prescribed for hypertensive patients, is particularly noteworthy in this context. This article aims to introduce a rapid, simple, improved sensitivity, and reproducibility in detecting AP in its pure form, tablet formulation, and spiked human plasma than the other reported methods. The proposed method utilizes a fluorescence approach, relying on the inhibition of the intramolecular photoinduced electron transfer (PET) effect of the lone pair of the N-atom in the primary amino moiety of AP. This inhibition is achieved by acidifying the surrounding medium using 0.2 M acetic acid. By blocking PET, the target AP drug is sensitively detected, at [Formula: see text] 423 nm over a concentration range 25-500 ng mL- 1 showcasing an exceptionally low quantitation limit of 1.41 ng mL- 1. Notably, this innovative technique was successfully applied to detect AP in its solid dosage form and spiked human plasma. Remarkably, matrix interference was found to be insignificant, underscoring the robustness and applicability of the established approach. The combination of speed, sensitivity, and reproducibility makes this method particularly suitable for assessing medication adherence in patients prescribed AP for hypertension.

Development and validation of a simple method for the determination of Atorvastatin calcium in pure and pharmaceutical formulations using spectrofluorimetry

A simple, accurate, precise, sensitive and selective spectrofluorimetric method was developed and validated for the determination of Atorvastatin calcium (ATV), an HMG-CoA reductase inhibitor, in its pure and tablet dosage form. The proposed method was based on direct measurement of the native fluorescence of ATV. Fluorescence analysis was accomplished by using an emission wavelength 385 nm after excitation at the wavelength of 270 nm in acetonitrile, without difficult preparation steps of the sample solution such as separation, extraction, pH adjustment or derivatization. All variables affecting the fluorescence intensity such as measurement time, temperature, and diluting solvent were investigated and optimized. Under the typical conditions, a validation study for linearity, range, accuracy, precision, selectivity and robustness of the proposed method was implemented according to ICH guidelines. The fluorescence intensity was linear over concentration range of (0.4-12) μg/ml (r = 0.9999), and the lower limits of detection and quantification were 0.079 and 0.24 μg/ml, respectively. Good accuracy and precision results were obtained through using the presented method with excellent mean recovery value 100.08 ± 0.32 which was in the acceptable range (98.0-102.0%), and RSD <2%, proving the precision of the developed method. Specificity was proved in the presence of excipients and Amlodipine besylate (AML) which encountered usually as combined drug with ATV. The developed method was successfully applied to the analysis of pharmaceuticals containing the mentioned drug with no interference from other drugs or dosage form additives, and the recoveries were in the range of 99.11 ± 0.75 to 100.89 ± 0.70. Furthermore, the obtained results were compared with reported HPLC method. Then, the t- and F- values were calculated and compared with the theoretical ones, which indicate good precision and high accuracy of the proposed method. Therefore, this method is valuable, reliable, and very suitable to be applied in routine quality control laboratories.

Simple spectrophotometric methods for the determination of amlodipine and atorvastatin in bulk and tablets

Background

Simultaneous spectrophotometric determination of samples containing more than one analyte presents analytical challenge; the choice of an analytical procedure is strictly related to the extent of overlapping between the individual absorption peaks of these components; if the absorption peaks are satisfactorily resolved, the determination is not problematic, but if the individual component signals are partly or totally overlapped, then powerful techniques are needed. Combined amlodipine and atorvastatin are typical example where special techniques are needed to resolve bands overlapping.

Results

Application of multiwavelength regression and absorbance factor methods to the analysis of atorvastatin and amlodipine combination proved to be satisfactorily capable of accurate and precise determination of the two analytes. The two methods recoveries were very close to the expected analytes concentrations, and the precision of the methods was < 2% relative standard deviation. Statistical comparison indicated that there is no significant difference between the assay results obtained by the two method as the calculated t values 0.91 and 1.13 for amlodipine and atorvastatin, respectively, were less than the tabulated t value 2.23 at 95% confidence level.

Conclusion

The proposed methods are accurate, precise, simple and inexpensive. They can be applied successfully to the analysis of the two drugs in combined dosage form.

Electrochemical sensing platform for the simultaneous femtomolar detection of amlodipine and atorvastatin drugs

The development of a proficient and ultra-high sensitive functionalized electrode for accurate analysis of drugs is a long-standing challenge. Herein, we report an electrochemical nanocomposite scaffold, comprising of silver nanoparticles integrated with functionalized carbon nanotubes (COOH-CNTs/Ag/NH₂-CNTs) for the simultaneous quantification of two widely used amlodipine (AM) and atorvastatin (AT) drugs. The sandwiched nanocomposite materials were thoroughly characterized morphologically and structurally. The nanocomposite COOH-CNTs/Ag/NH₂-CNTs immobilized over glassy carbon electrode catalyzed electron transfer reactions at the electrode–electrolyte interface and facilitated detection of targeted drugs, as revealed by the significant decrease in oxidation potentials at 879 mV and 1040 mV and improved current signals. Electrochemical characterization and testing show that the functionalized porous architecture with a large effective surface area is a promising scaffold for the sensing of a binary mixture of AM and AT with limits of detection in the femtomolar range (77.6 fM, and 83.2 fM, respectively). Besides, the specificity, stability, and reliability of the electrochemical sensing platform in simple and complex biological and pharmaceutical samples with high percentage recoveries highlight its scope for practical applications. Computational studies supported the experimental outcomes and offered insights about the role of modifier in facilitating electron transfer between transducer and analytes.

Development of an ultra-sensitive electrochemical platform for the simultaneous detection of two high blood pressure drugs.

Sensitive fluorescence detection of atorvastatin by doped carbon dots synthesized in deep eutectic media

Fluorescence properties of nanoparticles can be influenced by solvent. In this work, carbon dots (CDs) were synthesized in deep eutectic solvent by microwave assisted method. Quantum yield (QY) and size of the synthesized CDs were 41.3% and 2 nm, respectively. N/Cl -doped CDs had excellent sensitivity and selectivity for atorvastatin and detection limit was 0.8 nM. Simple and low-cost synthesis method and excellent sensitivity are advantages of this detection method for atorvastatin. The as-synthesized N/Cl-doped CDs were successfully used to determine atorvastatin in blood serum.

L-type Ca2+ channel blockers promote vascular remodeling through activation of STIM proteins

Voltage-gated L-type Ca2+ channel (Cav1.2) blockers (LCCBs) are major drugs for treating hypertension, the preeminent risk factor for heart failure. Vascular smooth muscle cell (VSMC) remodeling is a pathological hallmark of chronic hypertension. VSMC remodeling is characterized by molecular rewiring of the cellular Ca2+ signaling machinery, including down-regulation of Cav1.2 channels and up-regulation of the endoplasmic reticulum (ER) stromal-interacting molecule (STIM) Ca2+ sensor proteins and the plasma membrane ORAI Ca2+ channels. STIM/ORAI proteins mediate store-operated Ca2+ entry (SOCE) and drive fibro-proliferative gene programs during cardiovascular remodeling. SOCE is activated by agonists that induce depletion of ER Ca2+, causing STIM to activate ORAI. Here, we show that the three major classes of LCCBs activate STIM/ORAI-mediated Ca2+ entry in VSMCs. LCCBs act on the STIM N terminus to cause STIM relocalization to junctions and subsequent ORAI activation in a Cav1.2-independent and store depletion-independent manner. LCCB-induced promotion of VSMC remodeling requires STIM1, which is up-regulated in VSMCs from hypertensive rats. Epidemiology showed that LCCBs are more associated with heart failure than other antihypertensive drugs in patients. Our findings unravel a mechanism of LCCBs action on Ca2+ signaling and demonstrate that LCCBs promote vascular remodeling through STIM-mediated activation of ORAI. Our data indicate caution against the use of LCCBs in elderly patients or patients with advanced hypertension and/or onset of cardiovascular remodeling, where levels of STIM and ORAI are elevated.

A simple sonochemical assisted synthesis of NiMoO4/chitosan nanocomposite for electrochemical sensing of amlodipine in pharmaceutical and serum samples

In this investigation, a facile sonochemical route has been developed for the preparation of porous nickel molybdate nanosheets/chitosan nanocomposite (NiMoO₄/CHIT) by using ammonium molybdate and nickel(II) acetate tetrahydrate and as nickel and molybdate precursor, respectively (ultrasonic power 60 W/cm² and frequency 20 kHz). The ultrasonic based materials preparation as a fast, convenient and economical approach has been widely used to generate novel nanomaterials. Herein, we report an efficient voltammetric sensor for amlodipine drug by using porous nickel molybdate nanosheets/chitosan nanocomposite (NiMoO₄/CHIT). Its structure and properties were characterized by x-ray diffraction pattern, scanning electron microscope, transmission electron microscope, elemental analysis and mapping. The electrochemical studies are indicated the NiMoO₄/CHIT modified glassy carbon electrode (GCE) exhibited the good performance towards electrocatalytic sensing of amlodipine drug. Consequently, a linear correlation between the anodic peak current with sensor concentration 0.025-373.6 µM with a detection limit and sensitivity of 4.62 nM and 4.753 µA·µM^-1·cm^-2, respectively. A voltammetry based drug analysis was found to be high sensitive and reproducible, which able to detect nanomolar concentration. Furthermore, the fabricated electrochemical sensor was applied in drug and biological samples.

Simultaneous estimation of amlodipine and atorvastatin by micelle-augmented first derivative synchronous spectrofluorimetry and multivariate analysis

Five Selective, rapid and sensitive spectrofluorimetric methods were performed in this study for the simultaneous estimation of amlodipine besylate (AML) and atorvastatin (ATR) in their binary mixtures and combination polypills that are used for management of cardiovascular conditions. The first method depends on micelle-enhanced first derivative synchronous fluorimetric analysis (method I) and the other four methods are multivariate analysis techniques based on the use of factor-based calibration prediction methods comprising partial least squares (PLS), Principal Component Regression (PCR), genetic algorithm PLS (GA-PLS) and genetic algorithm PCR (GA-PCR). The synchronous fluorescence spectra of the solutions were measured at a constant wavelength difference; Δλ = 100 nm. The magnitudes of the peaks of the first derivative spectra (1D) were measured at 292 nm and 387 nm for ATR, and AML correspondingly. The multivariate models were constructed utilizing fifteen mixtures as a calibration set and ten mixtures as a validation set. The linearity of all the methods was in the concentration ranges of (0.1-4.0 μg mL^-1, 0.4-10.0 μg mL^-1) for AML and ATR, correspondingly. Statistical analysis revealed no significant difference between the proposed methods and the reference method. The validity of the proposed methods allows their suitability for quality control work. All the analysis settings were optimized and all the suggested procedures were applied productively for the determination of both drugs in synthetic mixtures, validation set, and combination polypills.

Development of UV spectrophotometry methods for concurrent quantification of amlodipine and celecoxib by manipulation of ratio spectra in pure and pharmaceutical formulation

Recently, the United States Food and Drug Administration approved a new oral dosage preparation of amlodipine besylate (AML) and celecoxib (CEL) for the management of hypertension and osteoarthritis. However, no simultaneous estimation procedures for these two analytes have been described. Hence, two simple, accurate, and precise ultraviolet spectroscopic procedures that manipulated the ratio spectra were established for concurrent quantification of AML and CEL using ethanol as a solvent. The first method involves determining the peak-to-trough amplitude difference of the ratio spectra of AML and CEL. The second method involves determining the peak amplitude of the ratio first derivative (Δλ 4 nm) spectra of AML and CEL at 334.2 nm and 254.2 nm, correspondingly. Both methods showed linearity in the range of 1–6 μg mL-1 for AML and 5–40 μg mL-1 for CEL with an excellent correlation coefficient (<0.999). The proposed procedures were validated by following the International Conference on Harmonization guidelines for accuracy, precision, selectivity, recovery, and stability studies. It is evident from the low %RSD and %RE that both analytical procedures were found to be accurate and precise, respectively. The percent recovery of AML and CEL from the formulation was found to be 99.79% and 99.34% using the ratio-difference method and 100.13% and 99.70% using the ratio first-derivative method, with a low percent relative standard deviation. Further, the proposed techniques permit concurrent quantification of AML and CEL in different concentration ratios without interference from each other; hence, these techniques can be adopted for regular quality-control studies.

Determination of amlodipine and atorvastatin mixture by different spectrophotometric methods with or without regression equations

Four new, simple, and reproducible spectrophotometric methods were developed and validated for the simultaneous determination of Amlodipine (AML) and Atorvastatin (AT) in bulk powder and pharmaceutical dosage form. The four methods include two progressive and two successive resolution techniques. The two progressive methods are Absorbance Subtraction (AS) and Amplitude Modulation (AM), while the two successive methods are Constant Value (CV) and Concentration Value. In the Concentration Value method, the concentration of the drugs is determined from the graphical representation without the use of regression equations. Linearity range for the two progressive methods was from 5 μg/mL-35 μg/mL while for the two successive methods was from 5 μg/mL-55 μg/mL. The four methods were validated according to the ICH guidelines and were found to be accurate, precise, and selective. The methods were also applied for determination of the mixture in the marketed pharmaceutical dosage form. Results obtained were compared with reported methods. Also, One-way ANOVA statistical test was done between all the proposed spectrophotometric methods where no significant differences were found.

Simultaneous magnetic dispersive micro solid phase extraction of valsartan and atorvastatin using a CMC-coated Fe3O4 nanocomposite prior to HPLC-UV detection: multivariate optimization

In this study, a sensitive, rapid, accurate and practical procedure is established for determination of atorvastatin and valsartan from human biological fluids by dispersive micro solid phase extraction (D-μ-SPE) combined with HPLC-UV detector.

Development and validation of simple simultaneous analysis for amlodipine and glibenclamide by nonderivatization high-performance liquid chromatography-fluorescence

Studies have shown that about 65% of diabetics have hypertension. Treatment for diabetic patients with hypertension is usually given a combination of drugs such as amlodipine (AML) and glibenclamide (GLI). The aim of this study was to develop and validate the simple simultaneous analysis method for separation of AML and GLI using high-performance liquid chromatography (HPLC) with fluorescence detector without derivatization. The arrangement of isocratic and gradient methods, mobile phase compositions, and flow rates to develop and validate the simple simultaneous analysis method for separation of AML and GLI by nonderivatization HPLC fluorescence was done. Optimum condition was obtained using an RP 18 (125 mm × 4 mm, i.d., 5 μm) and guard column RP 18 (4 mm × 4 mm, i.d., 5 μm) with mobile phase composition containing acetonitrile and phosphate buffer pH 3.0 using a 20:80 gradient condition at flow rate 1.0 ml/min measured at 361 nm for λ excitation and 442 nm for λ emission for AML and 235 nm for λ excitation and 354 nm for λ emission for GLI. The analysis of AML and GLI demonstrated a valid result with r ² value 0.999, recoveries were 100.04% and 99.14% relative standard deviations were 0.508% and 0,797%, respectively, detection limits were 0.055 and 0.104 μg/ml, and quantification limits were 0.166 and 0.316 μg/ml, respectively. An accurate method of separation for AML and GLI using HPLC with fluorescence detector without derivatization has been validated.

Development and validation of HPLC and CE methods for simultaneous determination of amlodipine and atorvastatin in the presence of their acidic degradation products in tablets

Two methods were developed for separation and quantitation of amlodipine (AML) and atorvastatin (ATV) in the presence of their acidic degradation products. The first method was a simple isocratic RP-HPLC method while the second was capillary electrophoresis (CE). Degradation products were obtained by acidic hydrolysis of the two drugs and their structures were elucidated for the first time by IR and MS spectra. Degradation products did not interfere with the determination of either drug and the assays were therefore stability-indicating. The linearity of the proposed methods was established over the ranges 1-50 μg mL-1 for AML and ATV in the HPLC method and in the range of 3-50 and 4-50 μg mL-1 for AML and ATV, respectively, in the CE method. The proposed methods were validated according to ICH guidelines. The methods were successfully applied to estimation of AML and ATV in combined tablets.